Companies Dominating the Pancreatic Adenocarcinoma Treatment Landscape
- Amgen Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- F. Hoffman-La Roche AG
- Novartis AG
- Pfizer Inc.
- Aduro Biotech Inc.
- Clovis Oncology Inc.
- Threshold Pharmaceuticals Inc.
- NewLink Genetics Corp
- Infinity Pharmaceuticals Inc.
- Celgene Corporation
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
Pancreatic Adenocarcinoma Treatment Market in 2025 is estimated at USD 2.92 billion.
The global market size was more than USD 2.62 billion in 2024 and is anticipated to grow at a CAGR of over 14.3%, reaching USD 14.89 billion revenue by 2037.
North America is likely to secure USD 4.91 billion by 2037, driven by the rising incidence of pancreatic adenocarcinoma.
The major players in the market include Amgen Inc., F. Hoffman-La Roche AG, Novartis AG, Pfizer Inc., Aduro Biotech Inc., Clovis Oncology Inc., Threshold Pharmaceuticals Inc., NewLink Genetics Corp, Infinity Pharmaceuticals Inc., Celgene Corporation
